LENZ Therapeutics, Inc. (LENZ)
| Market Cap | 446.60M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -124.65M |
| Shares Out | 25.53M |
| EPS (ttm) | -15.33 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | $7.21 (41.22%) |
| Ex-Dividend Date | Mar 22, 2024 |
| Volume | 85,604 |
| Open | 17.34 |
| Previous Close | 17.70 |
| Day's Range | 16.76 - 18.09 |
| 52-Week Range | 2.01 - 24.59 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 31.33 (+79.13%) |
| Earnings Date | May 26, 2024 |
About LENZ
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California. [Read more]
Analyst Forecast
According to 4 analysts, the average rating for LENZ stock is "Strong Buy." The 12-month stock price forecast is $31.33, which is an increase of 79.13% from the latest price.
News
Lenz Therapeutics' eye disease drugs meet main goal of late-stage study
Lenz Therapeutics said on Wednesday its experimental drugs to treat loss of near vision met the main goal of a late-stage study, sending its shares up nearly 23% before the bell.
LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials
SAN DIEGO--(BUSINESS WIRE)--LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop...
LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials
SAN DIEGO--(BUSINESS WIRE)--LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop...
LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress
SAN DIEGO--(BUSINESS WIRE)--LENZ Therapeutics, Inc. (Nasdaq: LENZ) (LENZ or the Company), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that...